Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Janux Therapeutics, Inc. Transaction History
Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.
- $846 Billion
- Q2 2025
A detailed history of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. holds 376,496 shares of JANX stock, worth $10.7 Million. This represents 1.03% of its overall portfolio holdings.
Number of Shares
376,496
Previous 376,496
-0.0%
Holding current value
$10.7 Million
Previous $10.2 Billion
14.44%
% of portfolio
1.03%
Previous 2.1%
Shares
3 transactions
Others Institutions Holding JANX
# of Institutions
187Shares Held
56MCall Options Held
869KPut Options Held
652K-
Ra Capital Management, L.P. Boston, MA11.2MShares$319 Million5.65% of portfolio
-
Janus Henderson Group PLC London, X04.46MShares$127 Million0.05% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.92MShares$83.3 Million3.15% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.53MShares$72 Million0.1% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$66.8 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.19B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...